Bluebird’s Zynteglo Shows Long-Term Efficacy And Safety Amid US Commercialization Push
Executive Summary
Data presented at ASH show patients maintaining transfusion independence for years after infusion, months after bluebird won FDA approval for the beta-thalassemia gene therapy.
You may also be interested in...
Busulfan-Induced Infertility May Deter Some Pediatric Patients From Bluebird, Other Gene Therapies
Ovum preservation and sperm banking are options for post-puberty patients, but busulfan – used for myeloablative conditioning before certain gene therapies – may cause hesitation to use some treatments in children, experts at ASH told Scrip.
Bluebird’s Zynteglo Launch Under Way, But First Revenue Will Take Months
Bluebird bio will not see revenue for Zynteglo until it is infused into beta-thalassemia patients, which will take months due to the ex vivo gene therapy’s complex manufacturing and quality control process.
Bluebird’s Zynteglo Approval Kicks Off Commercial Operations
Bluebird bio’s Tom Klima told Scrip launch preparations are well under way, including negotiations with payers on outcomes-based reimbursement agreements.